Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zbigniew Nowecki

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
The Lancet. Oncology|October 31, 2024
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trialMafalda Oliveira, Denys Pominchuk, Zbigniew Nowecki, et al.
Future Oncology (London, England)|June 30, 2023
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancerAditya Bardia, Komal Jhaveri, Kevin Kalinsky, et al.
The New England Journal of Medicine|June 2, 2025
First-Line Camizestrant for Emerging <i>ESR1</i>-Mutated Advanced Breast CancerFrançois-Clément Bidard, Erica L Mayer, Yeon Hee Park, et al.
The Lancet. Oncology|July 13, 2026
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trialNicholas C Turner, Erica L Mayer, Yeon Hee Park, et al.
The New England Journal of Medicine|March 20, 2024
Ribociclib plus Endocrine Therapy in Early Breast CancerDennis Slamon, Oleg Lipatov, Zbigniew Nowecki, et al.
The New England Journal of Medicine|December 10, 2025
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast CancerSibylle Loibl, Yeon Hee Park, Zhiming Shao, et al.
The New England Journal of Medicine|June 3, 2021
Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast CancerAndrew N J Tutt, Judy E Garber, Bella Kaufman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2021
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)Michael Gnant, Amylou C Dueck, Sophie Frantal, et al.
The Lancet. Oncology|January 18, 2021
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 studyErica L Mayer, Amylou C Dueck, Miguel Martin, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
The Lancet. Oncology|October 31, 2024
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trialMafalda Oliveira, Denys Pominchuk, Zbigniew Nowecki, et al.
Future Oncology (London, England)|June 30, 2023
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancerAditya Bardia, Komal Jhaveri, Kevin Kalinsky, et al.
The New England Journal of Medicine|June 2, 2025
First-Line Camizestrant for Emerging <i>ESR1</i>-Mutated Advanced Breast CancerFrançois-Clément Bidard, Erica L Mayer, Yeon Hee Park, et al.
The Lancet. Oncology|July 13, 2026
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trialNicholas C Turner, Erica L Mayer, Yeon Hee Park, et al.
The New England Journal of Medicine|March 20, 2024
Ribociclib plus Endocrine Therapy in Early Breast CancerDennis Slamon, Oleg Lipatov, Zbigniew Nowecki, et al.
The New England Journal of Medicine|December 10, 2025
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast CancerSibylle Loibl, Yeon Hee Park, Zhiming Shao, et al.
The New England Journal of Medicine|June 3, 2021
Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast CancerAndrew N J Tutt, Judy E Garber, Bella Kaufman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2021
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)Michael Gnant, Amylou C Dueck, Sophie Frantal, et al.
The Lancet. Oncology|January 18, 2021
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 studyErica L Mayer, Amylou C Dueck, Miguel Martin, et al.
Pageof 4